Aligos Therapeutics (NASDAQ:ALGS) Downgraded by Zacks Investment Research

Aligos Therapeutics (NASDAQ:ALGSGet Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday, Zacks.com reports.

According to Zacks, “Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is focused on the development of antiviral therapies for chronic hepatitis B and coronaviruses as well as liver diseases. Aligos Therapeutics, Inc. is based in SAN FRANCISCO, Calif. “

Several other brokerages have also commented on ALGS. SVB Leerink lowered shares of Aligos Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, May 5th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Aligos Therapeutics in a research note on Friday, April 1st. Finally, Piper Sandler cut shares of Aligos Therapeutics from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $15.00 to $4.00 in a research note on Wednesday, March 23rd. Five equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $6.15.

Shares of NASDAQ:ALGS traded up $0.05 during trading on Tuesday, hitting $1.15. 37,457 shares of the stock traded hands, compared to its average volume of 481,051. The stock has a market capitalization of $49.10 million, a P/E ratio of -0.35 and a beta of 3.52. The business’s fifty day simple moving average is $1.96. Aligos Therapeutics has a 52-week low of $1.03 and a 52-week high of $34.31.

Aligos Therapeutics (NASDAQ:ALGSGet Rating) last posted its earnings results on Wednesday, May 4th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.11). Aligos Therapeutics had a negative net margin of 2,263.64% and a negative return on equity of 75.34%. During the same quarter in the previous year, the business earned ($0.74) EPS. Sell-side analysts forecast that Aligos Therapeutics will post -2.7 EPS for the current fiscal year.

Hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC boosted its position in shares of Aligos Therapeutics by 22.8% during the 3rd quarter. Geode Capital Management LLC now owns 313,655 shares of the company’s stock valued at $4,864,000 after acquiring an additional 58,307 shares during the last quarter. BlackRock Inc. boosted its position in shares of Aligos Therapeutics by 14.3% during the 3rd quarter. BlackRock Inc. now owns 1,239,562 shares of the company’s stock valued at $19,227,000 after acquiring an additional 155,518 shares during the last quarter. Jump Financial LLC acquired a new position in shares of Aligos Therapeutics during the 3rd quarter valued at about $250,000. Two Sigma Investments LP acquired a new position in shares of Aligos Therapeutics during the 3rd quarter valued at about $1,394,000. Finally, Sphera Funds Management LTD. acquired a new position in shares of Aligos Therapeutics during the 3rd quarter valued at about $3,865,000. 70.21% of the stock is currently owned by hedge funds and other institutional investors.

Aligos Therapeutics Company Profile (Get Rating)

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB.

Read More

Get a free copy of the Zacks research report on Aligos Therapeutics (ALGS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Aligos Therapeutics (NASDAQ:ALGS)

Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.